Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 8256 participants.
Also called NCT02929329
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 8,256 participants
- Sponsor
- Registry
-
NCT02929329 -
2016-002299-28
-
- Other papers using this trial's data
- Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial
- Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
- Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study
- Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF
- Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial
- Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial
- Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial
- Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HF
- Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02929329. Randomized; triple masking; primary purpose treatment. Start 2017-01-06 (actual); primary completion 2020-09-14 (actual). Results posted on 2021-07-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
- Acronym
- GALACTIC-HF
- Condition
- Heart Failure
- Intervention (Drug)
- Omecamtiv Mecarbil
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Standard of Care
- Lead sponsor
- Cytokinetics
Record details
- Record id
cardio:ct-nct02929329- Content hash
1f3567d36fed402a428692fde6c9e192428591ddf37e8e1c011398c7e28755e6